AI
Saturday, September 01, 2012 3:18:01 PM
kt
"The terms of the loan provide enough time for a Phase 3 trial to reach completion "
The terms may provide enough time for a Phase III completion but not enough money. When is the loan due? We need a partner or license deal.
On average, it will cost a company $359 million to develop a new drug from the research lab to the patient.
http://ca-biomed.org/pdf/media-kit/fact-sheets/cbradrugdevelop.pdf
In 1975, bringing a drug to market cost $100 million in 2012-adjusted dollars. By 2005, that figure had exploded to more than $1.3 billion, according to numbers from the Tufts Center for the Study of Drug Development.
http://www.raps.org/focus-online/news/news-article-view/article/1359/report-phase-iii-clinical-trials-behind-increase-in-the-cost-of-pharmaceuticals.aspx
http://www.manhattan-institute.org/html/fda_05.htm
"The terms of the loan provide enough time for a Phase 3 trial to reach completion "
The terms may provide enough time for a Phase III completion but not enough money. When is the loan due? We need a partner or license deal.
On average, it will cost a company $359 million to develop a new drug from the research lab to the patient.
http://ca-biomed.org/pdf/media-kit/fact-sheets/cbradrugdevelop.pdf
In 1975, bringing a drug to market cost $100 million in 2012-adjusted dollars. By 2005, that figure had exploded to more than $1.3 billion, according to numbers from the Tufts Center for the Study of Drug Development.
http://www.raps.org/focus-online/news/news-article-view/article/1359/report-phase-iii-clinical-trials-behind-increase-in-the-cost-of-pharmaceuticals.aspx
http://www.manhattan-institute.org/html/fda_05.htm
